Table 2.

Longitudinal study of early and established Rheumatoid Arthritis patients treated with methotrexate or tofacitinib: clinical details.

Early RA – Methotrexate treatment
Disease duration (years)	0
Time	Basal	6 months
Size population (n)	25
Female/male (%)	75/25
Age (years)	61.24 ± 12.65
DAS-28	5.04 ± 1.20	2.94 ± 1.16***
CRP (mg/ml)	1.48 ± 1.90	0.78 ± 0.67*
Responders (%)	80
Long established RA – Tofacitinib treatment
Disease duration (years)	37.48 ± 11.79
Time	Basal	6 months
Size population (n)	25
Female/male (%)	70/30
Age (years)	63.75 ± 10.19
DAS-28	4.84 ± 0.70	3.33 ± 1.12***
CRP (mg/ml)	8.48 ± 7.53	3.51 ± 6.15**
Responders (%)	72

Data are represented by mean ± SD. HDs, Healthy donors; RA, Rheumatoid arthritis, DAS, disease activity score; CRP, c-reactive protein; *Significant differences vs basal time, p value < 0.05; **Significant differences vs basal time, p value < 0.01; ***Significant differences vs basal time, p value < 0.0001.